ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.680,20
-0,25%
S&P 500
5.307,01
-0,27%
Dow Jones
39.671,04
-0,51%
Euro vs US Dollar
1,08296
0,04%
Bitcoin
69.429,73
0,47%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Galectin Therapeutics Inc (GALT)

  7. Galectin Therapeutics Inc (GALT) News

GALT

Galectin Therapeutics (GALT)

Galectin Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:GALT
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202413h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GALTGalectin Therapeutics Inc
15/05/202413h50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GALTGalectin Therapeutics Inc
04/03/202418h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
07/02/202422h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
16/01/202417h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
02/01/202414h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
18/12/202314h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
11/12/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GALTGalectin Therapeutics Inc
07/12/202317h42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GALTGalectin Therapeutics Inc
01/12/202322h50Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
01/12/202322h38Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:GALTGalectin Therapeutics Inc
01/12/202314h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
15/11/202323h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
13/11/202315h21Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:GALTGalectin Therapeutics Inc
13/11/202314h45GlobeNewswire Inc.UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
13/11/202314h00GlobeNewswire Inc.Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
13/11/202313h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GALTGalectin Therapeutics Inc
13/11/202313h50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GALTGalectin Therapeutics Inc
03/11/202313h00GlobeNewswire Inc.Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDNASDAQ:GALTGalectin Therapeutics Inc
31/10/202321h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GALT

Kürzlich von Ihnen besucht

EU
VDPBO
Paris city public bonds
COIN
LTCUGBP
TSX
YXM.B
CI Morningstar US Moment...
NASDAQ
BLNKW
Blink Charging
COIN
PUBEEETH
PubeCoin
BSTP
PYUSDUSD
PayPal USD
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten